In an interview with newspaper The Edmonton Journal, CEO Michael Pearson said he wants to build on a current market share of the $20bn global skin care market that is currently estimated to be approximately 5 per cent.
Last week the company announced the acquisition of Janssen Pharmaceutical for an estimated $345m, as well as the planned $424m acquisition Sanofi's Dermik skin care business.
It is estimated that the two planned acquisitions should push Valiant's annual turnover from skin care products above the $1bn mark.